Clarithromycin , nanoclarithromycin


Published on

A nanomedicine for clarithromycin from

Published in: Health & Medicine, Business
  • Be the first to comment

  • Be the first to like this

No Downloads
Total views
On SlideShare
From Embeds
Number of Embeds
Embeds 0
No embeds

No notes for slide

Clarithromycin , nanoclarithromycin

  1. 1. Nanomedicine for Clarithromycin From
  2. 2. OPPORTUNITY According to Chinese Business Association reported that in 2007, with erythromycin-based macrolide antibiotics, total global sales of more than 90 million sales of clarithromycin in the global market has risen to 15 billion U.S. dollars, accounting for international macrolide antibiotics 18% of total sales, of which Abbott's patentname drugs clarithromycin only half of the remaining shares are contributed by imitation. Because clarithromycin Preparation Popular hospital in the country, the domestic pharmaceutical manufacturers spotted the opportunity to develop the production of clarithromycin Join us to take NanoClarithromycin to Clinic
  3. 3. What is Needed? Emulsifier is an egg phosphatide. No Need of It! Bio-available at all pH in all parts of digestive system in oral delivery formulations. pH independence needed. Soybean oil, an egg phosphatide, oleic acid, hexanoic acid and glycerin elimination fro formulations. Zero Need Of It! An effective, safe and most inexpensive nanomedicine for Clarithromycin. It is Needed! To eliminate acids from formulation. Take It out !
  4. 4. PROBLEM
  5. 5. Issues & Needs It has been found that erythromycin fat emulsions are locally non-irritative. The antibiotic clarithromycin, however, has a low solubility in fat emulsions even in the presence of oils, and will precipitate out of such emulsions. It has heretofore not been possible to solubilize clarithromycin so as to achieve stable injectable compositions at concentrations which are high enough for therapeutically effective pharmaceutical purposes. There is a continuing need for stable injectable compositions of clarithromycin at therapeutically acceptable concentrations that do not cause severe pain at the injection site. A genuine Project for investment
  6. 6. What is new? Present invention releases drug at all pH and faster than any existing formulation. Invention for nanomedicine Patented nanomedicine to prevent generic cliff Most inexpensive manufacturing of nanomedicines. Your manufacturing set-up remains same.
  7. 7. Why the market so big( $15Billion Market?) Multiple uses
  8. 8. Competition For Me-too Brands
  9. 9. CUSTOMERS ng Our customers for NanoClarithromycin Click hyperlink to see our customers
  10. 10. What has been Established SOP for pilot scale production Analytical testing procedures for testing Raw material Lab. Testing
  11. 11. Funds For To move in cGMP manufacturing Clinical trials Marketing
  12. 12. % of strains NCCLS Susceptible breakpoint PK/PD H. influenzae Clarithromycin S. pneumoniae Clarithromycin 0.25 8 ALL ORGANISMS 0.25 PK/PD breakpoint based on current approved dosing regimens 70 60 M. catarrhalis 50 40 S. pneumoniae 30 20 H. influenzae 10 0 0.03 0.12 0.5 2 MIC in ug/mL Alexander Project USA 2000 8 32 Solubility is a genuine need Resolved by Meda Biotech llc.
  13. 13. Technology 1. 2. 3. 4. 5. 6. New molecule MR007 for nanoparticle MR007 provides synergistic Lowest manufacturing cost Strong patent No need of existing facility change No need to hire new staff 1.
  14. 14. Available Capsules Tablets potent Stable and 10X more Syrup Injectable Nanomedicine for all
  15. 15. Contact Mewa Singh, PhD 609-902-7128 Meda Biotech,llc. Baton Rouge, LA 70803